1.2 List of Figures
Figure 1: Cardiovascular Disease Drugs Market, Global, Epidemiology Patterns for Hypertension, 2016-2023 24
Figure 2: Cardiovascular Disease Drugs Market, Global, Epidemiology Patterns for Dyslipidemia, 2016-2023 25
Figure 3: Cardiovascular Disease Drugs Market, Global, Epidemiology Patterns for Heart Failure, 2016-2023 26
Figure 4: Cardiovascular Disease Drugs Market, Global, Key Marketed Products and Approved Indications, 2017 37
Figure 5: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Lipitor ($bn), 2006-2023 39
Figure 6: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Crestor ($bn), 2006-2023 40
Figure 7: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Zetia ($bn), 2006-2023 41
Figure 8: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Praluent ($bn), 2015-2023 43
Figure 9: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Repatha ($bn), 2016-2023 44
Figure 10: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Plavix ($bn), 2006-2023 45
Figure 11: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Xarelto ($bn), 2011-2023 47
Figure 12: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Eliquis ($bn), 2012-2023 48
Figure 13: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Brilinta ($bn), 2011-2023 49
Figure 14: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Entresto ($bn), 2015-2023 51
Figure 15: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Benicar ($bn), 2006-2023 52
Figure 16: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Bevyxxa ($m), 2017-2023 53
Figure 17: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Uptravi ($bn), 2016-2023 54
Figure 18: Cardiovascular Disease Drugs Market, Global, Annual Revenue for Opsumit ($bn), 2013-2023 56
Figure 19: Cardiovascular Disease Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017 59
Figure 20: Cardiovascular Disease Drugs Market, Global, Pipeline by Stage of Development and Molecule Type, 2017 60
Figure 21: Cardiovascular Disease Drugs Market, Global, Pipeline for Key Cardiovascular Disease Indications by Stage of Development, 2017 62
Figure 22: Cardiovascular Disease Drugs Market, Global, Pipeline for Key Cardiovascular Disease Indications by Molecule Type, 2017 63
Figure 23: Cardiovascular Disease Drugs Market, Global, Pipeline by Molecular Target and Stage of Development, 2017 65
Figure 24: Cardiovascular Disease Drugs Market, Global, Pipeline by Molecular Target Breakdown, 2017 66
Figure 25: Cardiovascular Drugs Market, Global, Pipeline for Key Cardiovascular Disease Indications by Molecular Target, 2017 67
Figure 26: Cardiovascular Disease Drugs Market, Global, Clinical Program Attrition Rates by Stage of Development (%), 2006-2017 68
Figure 27: Cardiovascular Disease Drugs Market, Global, Clinical Trial Failure Rates (Phases I-III) and Overall Clinical Trial Attrition Rates by Indication (%), 2006-2017 69
Figure 28: Cardiovascular Disease Drugs Market, Global, Clinical Trial Failure Rates (Phases I-III) and Overall Clinical Trial Attrition Rates by Molecule Type (%), 2006-2017 70
Figure 29: Cardiovascular Disease Drugs Market, Global, Clinical Trial Failure Rates (Phases I-III) and Overall Clinical Trial Attrition Rates by Molecular Target (%), 2006-2017 71
Figure 30: Cardiovascular Disease Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017 72
Figure 31: Cardiovascular Disease Drugs Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017 73
Figure 32: Cardiovascular Disease Drugs, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2017 74
Figure 33: Cardiovascular Disease Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2017 75
Figure 34: Cardiovascular Disease Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2017 76
Figure 35: Cardiovascular Disease Drugs Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2017 77
Figure 36: Cardiovascular Disease Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2017 78
Figure 37: Cardiovascular Disease Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2017 79
Figure 38: Cardiovascular Disease Drugs Market, Global, Aggregate Clinical Program Size by Stage of Development (participants), 2006-2017 80
Figure 39: Cardiovascular Disease Drugs Market, Global, Aggregate Clinical Program Size by Stage of Development and Indication (participants), 2006-2017 81
Figure 40: Cardiovascular Disease Drugs Market, Global, Aggregate Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2017 82
Figure 41: Cardiovascular Disease Drugs Market, Global, Aggregate Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2017 83
Figure 42: Cardiovascular Disease Drugs Market, Global, Revenue Forecast for Inclisiran ($bn), 2020-2023 85
Figure 43: Cardiovascular Disease Drugs Market, Global, Revenue Forecast for MEDI-6012 ($m), 2020-2023 86
Figure 44: Cardiovascular Disease Drugs Market, Global, Revenue Forecast for Volanesorsen ($m), 2018-2023 89
Figure 45: Cardiovascular Disease Drugs Market, Global, Revenue Forecast for Vericiguat ($m), 2019-2023 91
Figure 46: Cardiovascular Disease Drugs Market, Global, Revenue Forecast for Bempedoic acid ($m), 2019-2023 93
Figure 47: Cardiovascular Disease Drugs Market, Global, Market Size ($bn), 2016-2023 95
Figure 48: Cardiovascular Disease Drugs Market, Global, Key Products Market Share, 2016-2023 99
Figure 49: Cardiovascular Drugs Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2016-2023 100
Figure 50: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for Drugs Targeting Elements of the Coagulation Cascade ($bn), 2016-2023 103
Figure 51: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for Drugs Acting on RAS ($bn), 2016-2023 104
Figure 52: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for P2Y12 Inhibitors ($bn), 2016-2023 105
Figure 53: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for HMG-CoA Inhibitors ($bn), 2016-2023 106
Figure 54: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for PCSK9 Inhibitors ($bn), 2016-2023 107
Figure 55: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for Beta Blockers ($bn), 2016-2023 108
Figure 56: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for Drugs Acting on Prostaglandin Receptors ($bn), 2016-2023 109
Figure 57: Cardiovascular Disease Drugs Market, Global, Annual Revenue Forecast for Drugs Acting on Endothelin Receptors ($bn), 2016-2023 110
Figure 58: Cardiovascular Disease Drugs Market, Global, Cluster by Growth and Market Share, 2016-2023 111
Figure 59: Cardiovascular Disease Drugs Market, Global, Company Analysis Matrix, 2017 112
Figure 60: Cardiovascular Disease Drugs Market, Global, Forecast Market Share by Company (%), 2016-2023 115
Figure 61: Cardiovascular Diseasse Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2016-2023 116
Figure 62: Cardiovascular Disease Drugs Market, Global, Sanofi Annual Revenue Forecast, 2016-2023 117
Figure 63: Cardiovascular Disease Drugs Market, Global, AstraZeneca Annual Revenue Forecast, 2016-2023 118
Figure 64: Cardiovascular Disease Drugs Market, Global, Novartis Annual Revenue Forecast, 2016-2023 119
Figure 65: Cardiovascular Disease Drugs Market, Global, Bayer Annual Revenue Forecast, 2016-2023 120
Figure 66: Cardiovascular Disease Drugs Market, Global, Pfizer Annual Revenue Forecast, 2016-2023 121
Figure 67: Cardiovascular Disease Drugs Market, Global, Johnson and Johnson, Annual Revenue Forecast, 2016-2023 122
Figure 68: Cardiovascular Disease Drugs Market, Global, Bristol-Myers Squibb, Annual Revenue Forecast, 2016-2023 123
Figure 69: Cardiovascular Disease Drugs Market, Global, Merck & Co, Annual Revenue Forecast, 2016-2023 124
Figure 70: Cardiovascular Disease Drugs Market, Global, High-Activity and Late-Stage Pipeline Developers by Type, 2017 125
Figure 71: Cardiovascular Disease Drugs Market, Global, Pipeline, Overall, High-Activity and Late-Stage Developers by Level of Cardiovascular Specialization, 2017 126
Figure 72: Cardiovascular Disease Drugs Market, Global, Proportion of Total Company Revenue Attributed to Cardiovascular Disease, 2016-2023 127
Figure 73: Cardiovascular Disease Drugs, Global, Licensing Deals by Region, Value and Year, 200`6-2017 129
Figure 74: Cardiovascular Disease Drugs Market, Global, Licensing Deals by Indication, 2006-2017 130
Figure 75: Cardiovascular Disease Drugs, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2017 131
Figure 76: Cardiovascular Disease Drugs Market, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target, 2006-2017 132
Figure 77: Cardiovascular Disease Drugs Market, Global, Licensing Deals with Disclosed Deal Values, 2006-2017 133
Figure 78: Cardiovascular Disease Drugs, Global, Co-development Deals by Region, Value and Year, 2006-2017 135
Figure 79: Cardiovascular Drugs Market, Global, Co-development Deals by Indication, 2006-2017 136
Figure 80: Cardiovascular Disease Drugs Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017 137
Figure 81: Cardiovascular Disease Drugs Market, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target, 2006-2017 138
Figure 82: Cardiovascular Disease Drugs Market, Global, Co-development Deals with Disclosed Deal Values, 2006-2017 139